Recombinant Human EMAP-II protein

Background

Endothelial-Monocyte Activating Polypeptide II (EMAP-II) is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.

Expression system

Escherichia coli.

Purity

> 98 % by SDS-PAGE and HPLC analyses.

Molecular weight

Approximately 18.2 kDa, a single non-glycosylated polypeptide chain containing 166 amino acids.

Endotoxin

Less than 1 EU/μg of rHuEMAP-II as determined by LAL method.

Form

Sterile Filtered White lyophilized (freeze-dried) powder. Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Packaging image shown for reference. Select a size from the available options.